Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 13Breast Neoplasms 12Colorectal Neoplasms 11Ovarian Neoplasms 10Recurrence 9Neoplasms 9Small Cell Lung Carcinoma 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Large B-Cell, Diffuse 7Prostatic Neoplasms 6Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Carcinoma 5Multiple Myeloma 4Lymphoma, Follicular 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Mesothelioma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Kidney Neoplasms 3

Interventions

fludarabine phosphate 23Cyclophosphamide 23Whole-Body Irradiation 20Mycophenolic Acid 17Peripheral Blood Stem Cell Transplantation 15Busulfan 14Cyclosporine 12Tacrolimus 10Melphalan 10Antilymphocyte Serum 9Cord Blood Stem Cell Transplantation 7Rituximab 6Radiotherapy 6Methotrexate 6Filgrastim 6Etoposide 6fludarabine 5Methylprednisolone 5Granulocyte Colony-Stimulating Factor 4Vincristine 3Thiotepa 3Sirolimus 3Prednisone 3Methylprednisolone Hemisuccinate 3Methylprednisolone Acetate 3Doxorubicin 3Cytarabine 3Carboplatin 3Alemtuzumab 3thymoglobulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Dendritic Cell Sarcoma, Interdigitating × durvalumab × Clear all
NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡